A. Gordon

HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy

J. Torre-Cisneros, M. Frias, D. Rodriguez-Cano, 2016, The Pharmacogenomics Journal.

SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants

V. Simon, F. Krammer, A. Gordon, 2022, medRxiv.

KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

M. Frias, D. Rodriguez-Cano, A. Gordon, 2016, The Pharmacogenomics Journal.

Rural habitat as risk factor for hepatitis E virus seroconversion in HIV‐infected patients: A prospective longitudinal study

L. Real, J. Torre-Cisneros, F. Cuenca-López, 2017, Zoonoses and public health.

High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients.

J. Torre-Cisneros, A. Gordon, J. Pineda, 2015, The Journal of infection.

Absence of occult Hepatitis E virus infection among HIV immunosuppressed patients.

J. Torre-Cisneros, A. Gordon, J. Pineda, 2015, The Journal of infection.

Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response

J. Torre-Cisneros, F. Cuenca-López, A. Gordon, 2015, PloS one.

Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance

L. Real, A. Gordon, J. Pineda, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients

J. Torre-Cisneros, A. Gordon, J. Pineda, 2014, PloS one.